Eye problems like glaucoma, ocular hypertension and esotropia are treated with the drug called Echothiophate iodide. It lessens the wpressure in the ocular area by increasing the drained fluids’ amount from the eye. Nervous strain is likewise lowered because the pupils get smaller, thus lessening sensitivity to light and darkness.
The drug mainly focuses on decreasing the pressure that is responsible for worsening glaucoma. Fluid that causes the visual impairmnet from the elevated intravascular pressure in the optic tract is addressed, too. It also helps the eye focus on objects more properly, thus making it potentially effective for people who suffer from esotropia.
This drug is grouped with parasympathomimetics. An anticholinesterase inhibitor, it combines with the cholinesterase so that the wanted effect would come about. The process is a rather slow one, and it usually takes weeks for the substance to be used completely.
Patients with eye disorders that all trace back to fluid retention and the buildup of eye fluids are usually the people who get this drug as a recommendation. For glaucoma patients, though, it’s different. Since glaucoma is an eye disorder that does not normally exhibit signs (and only does when the disease is almost beyond control), the drug is not administered. Rather, it becomes a maintaining drug in the case of fluid buildup from irritation and manipulation of the eyes.
Patients who encounter the same symptoms don’t get to use the drug as well. This is because there are always other reasons for a patient’s problem with proper vision.
This drug is administered to patients (especially children) with esotropia as it can help correct interocular pressure. Also, the chances for better eye muscle control and movement, particularly concerning focal control and management, are increased.
The dosage given to a patient depends on the type or eye disease. Echothiophate iodide is usually recommended at 0.03% solution for patients with early glaucoma. For those who developed the disease after a cataract injury and related disorders, the dosage may increase to 0.06%, 0.125% or 0.25%.
The treatment period using this drug is relatively low. A patient has the privilege of extending it, though, as long as he or she is reacting well to the drug. But, in the case of treatment cessation in which eye disorders have started to crop back up, surgery is recommended. That goes for the aforementioned diseases above so that the disorder/s can be corrected.
Though expected, the following side-effects from the drug need to be monitored properly: cloudy peripheral vision, tears, inflammation of the iris, twitching and stinging of the eyes, and blurred vision.
The drug is not working well for a patient if he or she manifests inflammation of the eye, angle-closure glaucoma and hypersensitivity to it.
- The molecular weight of echothiophate iodide is 383.228 g/mol
- Its chemical IUPAC name is 2-diethoxyphosphorylsulfanylethyl-trimethyl-ammonium iodide
- It has a molecular formula of C9H23INO3PS
Generic Name: Echothiophate Iodide Ophthalmic
Brand Name: Phospholine Iodide
Related Medications: Carboptic, Combigan, Corgard, Daranide, Diamox, Eserine Sulfate Ophthalmic, Iopidine, Isopto Carbachol, Isopto Carpine, Miostat, Neptazane, Pilocar, Pilopine HS, Pilostat
User Reviews for Echothiophate Iodide
Share your experience with other customers.Review This Drug